Suraksha Diagnostic Ltd. · NSE:SURAKSHA
Suraksha Diagnostic — Q4 FY26 Earnings Presentation
51 slides from Suraksha Diagnostic's earnings presentation, May 21, 2026
Slide 1: Exchange filing cover letter for investor presentation
Date: 21 May 2026 To The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol : SURAKSHA Dear
Slide 2: Suraksha Diagnostic Limited Investor Presentation Q4 & FY26
SURAKSHA DIAGNOSTIC LIMITED Investor Presentation | Q4 & FY26
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 4: Q4 & FY26 Highlights
Suraksha Clinic & Diagnostics Q4 & FY26 Highlights
Slide 5: Management Commentary on Q4 and FY26 Results
Management Commentary on Q4 and FY26 Results We are pleased to report a strong close to FY26, with revenue growing 23% year-on-year, reflecting the continued momentum in our core diagnostics business and the successful ramp-up of our newer centres. EBIDTA margins have also grown 16% year-on-year, re
Slide 6: Business at a Glance
Business at a Glance as of 31 March 2026 8 1.37 million 8.16 million ₹ 388 million Labs Patients Served Tests Performed Revenue per lab (FY26) (FY26) (FY26) 68 16 29 ₹ 2,264 Diagnostic Centres MRI Machines Revenue per patient CT Machines (FY26) 193 4 360 ₹ 719 NABL accredited EBITDA per patient Coll
Slide 7: Key Financial Performance for Q4 FY26
Key Financial Performance for Q4 FY26 Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 30.7% 30.6% 30.9% 11.0% 9.3% 7.6% +25% +26% -14% 822 252 72 783 238 72 659 62 200 Q4 FY25 Q3 FY26 Q4 FY26 Q4 FY25 Q3 FY26 Q4 FY26 Q4 FY25 Q3 FY26 Q4 FY26 Suraksha Diagnostic Limited| Investor Presentati
Slide 8: Key Financial Performance for FY26
Key Financial Performance for FY26 Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 33.8% 31.8% 12.3% 10.1% +23% +16% +1% 3,136 986 314 310 851 2,559 FY25 FY26 FY25 FY26 FY25 FY26 Suraksha Diagnostic Limited| Investor Presentation 7
Slide 9: Key Performance Indicators for FY26
Key Performance Indicators for FY26 Particulars Units FY26 Particulars Units FY26 Particulars Units FY26 Unit in (₹ in Number of tests per patient^ Unit 5.95 Number of tests performed 8.16 Revenue from operations 3,104.14 million million) Revenue generated from East Number of Small centres Unit 34 (
Slide 10: Statement of Profit & Loss (Consolidated)
Statement of Profit & Loss (Consolidated) Particulars (₹ million) Q4 FY26 Q4 FY25 Y-o-Y Q3 FY26 Q-o-Q FY26 FY25 Y-o-Y Revenue from Operations 814.12 650.95 776.87 3,104.14 2520.93 Other Income 7.85 8.17 6.22 31.64 38.46 Total Revenue 821.97 659.12 24.7% 783.09 5.0% 3135.78 2559.39 22.5% Cost of Mate
Slide 11: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) Particulars (₹ million) FY26 FY25 Particulars (₹ million) FY26 FY25 Property, plant and equipment 1,935.79 1,471.37 Equity share capital 104.16 104.16 Capital work-in-progress 351.16 100.99 Other equity 2,344.33 2,008.24 Right-of-use assets 1160.55 742.90 Equity attribut
Slide 12: Cash Flow Statement (Consolidated)
Cash Flow Statement (Consolidated) Particulars (₹ million) FY26 FY25 Particulars (₹ million) FY26 FY25 Cash flow from operating activities Other financial liabilities 15.23 9.15 Profit before tax 445.57 414.05 Provisions 5.87 1.04 Adjustments for: Cash generated from operations 951.87 739.41 Depreci
Slide 13: EBITDA Margin (%) Breakdown by Center Age
EBITDA Margin (%) Breakdown by Center Age Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Average EBITDA Average EBITDA Average EBITDA Average EBITDA Revenue Margin (%) Revenue Margin (%) Revenue Margin (%) Revenue Margin (%) per centre per centre per centre per centre (₹ million) 34.0% (₹ million) 31.7% (₹ million
Slide 14: Efficiency Gap between Mature and New Centres
Efficiency Gap between Mature and New Centres 6 50.0% 5.35 Average Monthly Revenue per centre (₹ million) 5 40.0% 30.0% EBITDA Margin (%) 4 20.0% 3 10.0% 2 1.43 0.0% 1 -10.0% 0 -20.0% Mature centres (> 2 yrs) New centres (< 2 yrs) Suraksha Diagnostic Limited| Investor Presentation 13
Slide 15: Key Developments and Expansion
Key Developments and Expansion
Slide 16: Expanded Offerings Through Strategic Acquisition
Expanded Offerings Through Strategic Acquisition ABOUT FETOMAT • Incorporated in May 2021, Fetomat Wellness Private Limited (“Fetomat”) is a network of fertility and pregnancy care clinics • Fetomat focuses on pregnancy care, women’s ultrasound scans, prenatal diagnostics, genetic counselling and me
Slide 17: Genomics could be the Next Growth Lever
Genomics could be the Next Growth Lever About Genomics Vertical Global Genetic Testing Market Size ($ billion) 186.64 • In July 2025, we announced the launch of Suraksha Genomics, a new vertical for advanced genetic and molecular testing services • Suraksha Genomics offers robust infrastructure and
Slide 18: Genomic Lab Suraksha- Your blueprint for life, secured
Genomic Lab Suraksha- Your blueprint for life, secured The Suraksha advantage Why choose Genomic Lab Suraksha? We don't just sequence DNA; we protect our patient’s most personal o Speed: data while delivering life-altering insights. Rapid TAT (Turnaround Time) for critical neonatal and oncology repo
Slide 19: MRI Integration at CMC
MRI Integration at CMC Introduction of next-generation 1.5 Tesla Helium-Free MRI technology at CMC The facility will deliver high-quality imaging with reduced helium dependency, enhancing diagnostic capabilities across neurology, orthopedics, cardiology, and oncology, improving operational efficienc
Slide 20: Expansion Plans – Centres FY27
Expansion Plans – Centres FY27 Bihar Bihar West Bengal 1 HUB 3 HUB 8 SPOKE Tripura Tripura Jharkhand West Bengal 1 HUB 1 HUB Jharkhand Suraksha Diagnostic Limited| Investor Presentation 19
Slide 21: Glimpses of Centre Expansion in FY26 (1/2)
Glimpses of Centre Expansion in FY26 (1/2) Suraksha Diagnostic Limited| Investor Presentation 20
Slide 22: Glimpses of Centre Expansion in FY26 (2/2)
Glimpses of Centre Expansion in FY26 (2/2) Suraksha Diagnostic Limited| Investor Presentation 21
Slide 23: Company Overview
Suraksha Clinic & Diagnostics Company Overview
Slide 24: Vision, Mission and Values
Vision, Mission and Values Medium-term Long-term We aspire to metamorphise the Company into the most reputable and Our vision is to be the most trusted and innovative diagnostic centre and cutting-edge diagnostic facility, providing precise, prompt, affordable set the standard for diagnostics in the
Slide 25: Evolution to the Largest Integrated Diagnostic Chain in East India
Evolution to the Largest Integrated Diagnostic Chain in East India Received second round of funding from OrbiMed Exit of Lighthouse Funds IPO and listing on Built fully BSE and NSE comprehensive diagnostic centre, 4 Labs 9 Labs under brand ‘Suraksha’ 1 centre 5 centres 25 centres 53 centres 68 centr
Slide 26: Deeply Entrenched in the Vital Geography of West Bengal
Deeply Entrenched in the Vital Geography of West Bengal 66 Centers in West Bengal 2 1 No. of centres >10 centres 1 4 to 10 centres 3 centres 2 centres Bihar Assam 1 centre • 4th most populous state in India • Fragmented market with low penetration of Population Legend Meghalaya chained diagnostic ce
Slide 27: Hub & Spoke Operating Model
Hub & Spoke Operating Model Modalities Offered Key Stats # of doctors & Area Hub Centres employees / centre Large Gastroenterology Dexa OPG Mammo Centres 30-40 5,000 – 8,000 sq. ft CT Scan Neurology USG X-Ray Cardiology Pathology Medium 20-25 2,500 – 5,000 sq. ft Centres CT-Scan Neurology USG X-Ray
Slide 28: …..With Demonstrated Success
…..With Demonstrated Success Demonstrated success in Kolkata region with significant potential Operational Network(1) for future growth2 1 Central Lab (equipped to conduct all pathology 7 Satellite Labs 16 Hub Centres sample collection, basic and advanced radiology tests) (co-located with hub centre
Slide 29: Well-established Operational Network - Greater Economies of Scale
Well-established Operational Network - Greater Economies of Scale Report Flow Patient P.A.C.S RAD IMAGE (Software) (Scrutiny) (Report) Image/Report Flow Image Flow Patients Flow #16 #1 Hub Centre Flagship Reference Lab Doctor #7 #46 Spoke Centre SATELLITE LAB Polyclinic Doctor Customers Samples Coll
Slide 30: Well Equipped Clinical Infrastructure
Well Equipped Clinical Infrastructure Suraksha Diagnostic Limited| Investor Presentation 29
Slide 31: Customer Convenience Through Value Added Services
Customer Convenience Through Value Added Services Value Added Services enhancing customer experience and convenience Home Collection Allows samples to be collected from the consumers’ locations, such as their homes or offices SMS Alerts Customers receive an SMS to Customer download the report throug
Slide 32: Positioned to Leverage IT Infrastructure
Positioned to Leverage IT Infrastructure Suraksha’s Integrated System for Diagnostics LIMS Integration RIS and PACS Advanced ERP-enabled Error Reduction and Workflow Imaging Tools Operations Turnaround Time Our Laboratory The Radiology PACS includes DICOM Our ERP system handles Automation reduces In
Slide 33: Experienced Board Of Directors
Experienced Board Of Directors Dr. Somnath Chatterjee Ritu Mittal Mr. Satish Kumar Verma Chairman & Joint Managing Director Joint Managing Director & Chief Non-Executive, Non-Independent Director Executive Officer ▪ Associated with Suraksha since ▪ 41+ years of experience in management ▪ Associated
Slide 34: Dynamic And Diverse Management Team to Deliver Next Phase of Growth
Dynamic And Diverse Management Team to Deliver Next Phase of Growth Ravindra K S Mamta Jain Niren Kaul Group Chief Financial Officer Company Secretary & Compliance Officer Chief Sales Officer ▪ Professional with over 21+ years of extensive experience ▪ 23+ years of experience, including with Bharti
Slide 35: Marquee Shareholders Invested in our Story
Marquee Shareholders Invested in our Story Shareholding Pattern as at 31st March 2026 13.46% 49.09% 23.14% 14.31% FIIs DIIs Others Promoter & Promoter Group Source: BSE DIIs include Mutual Funds, AIFs and Central / State governments FIIs include Foreign Direct Investments and Foreign Portfolio Inves
Slide 36: Key Awards & Recognition
Key Awards & Recognition 2017 2019 2021 Best quality in service delivery(1) Best customer service in healthcare(1) Business leader of the year(2) 2021 2022 2023 Certificate of excellence Outstanding diagnostic chain of Awards & certificate of excellence(3) in exemplary trust & commitment eastern Ind
Slide 37: Strategy & Outlook
Clinic & Diagnostics Strategy & Outlook
Slide 38: Leveraging Strengths to Drive Competitive Advantage
Leveraging Strengths to Drive Competitive Advantage Largest diagnostic chain with a Technologically advanced Track record of profitability dominant position in Eastern clinical infrastructure and and consistent financial India; well-positioned to benefit trained personnel ensuring performance from t
Slide 39: Strategic Levers to Drive Future Growth
Strategic Levers to Drive Future Growth Expand footprint in Eastern and Enhance one-stop diagnostic North-Eastern India through model by augmenting medical organic as well as inorganic consultation services’ share route Strengthen B2B and Invest in technology to institutional partnerships to enhance
Slide 40: Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets
Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets Expand in adjacent geographies of Eastern and Consolidate leading position in the core geography Supplement organic growth with selective acquisitions North-Eastern India Open additional diagnostic centres and increase Identi
Slide 41: Key Differentiating Factors
Key Differentiating Factors Polyclinic Diversified in terms of revenue from services % of FY26 Revenue 49% 44% 7% Pathology Radiology Other 160+ 1,000+ Chambers1 Doctors1 Omnichannel medical consultation services via online and offline modes through Other includes Revenue from Doctor Consultancy and
Slide 42: Industry Overview
Clinic & Diagnostics Industry Overview
Slide 43: Industry: Poised For High Growth; Shifting Towards Organized Market
Industry: Poised For High Growth; Shifting Towards Organized Market Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28 Organized players gaining market share from standalone labs at a steady rate CAGR 10-12% 1,275-1,375 36-40% 36-40% 860-870 13- 20- 17% 24% 45-49% 35-39% FY24E FY2
Slide 44: Eastern India - An Underserved Market With Premium Pricing
Eastern India - An “Underserved” Market With Premium Pricing Disparity in access to accredited testing services in Region has the lowest number of NABH East India(1) market also offers premium Eastern(1) India relative to population needs accredited hospitals pricing for diagnostic tests 430 80-90 8
Slide 45: Historical Financials and Operating Metrics
Historical Financials and Operating Metrics
Slide 46: Consolidated Financial Performance – Historical
Consolidated Financial Performance – Historical Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 25.0% 33.7% 33.8% 31.8% 3.2% 10.6% 12.3% 10.1% +62% +107% +415% 3,136 986 314 310 851 2,559 736 231 2,223 1,937 475 61 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Suraksha Diag
Slide 47: Consistent Performance Over the Years
Consistent Performance Over the Years Number of Centres Number of Patients (million) Number of Tests (million) 68 1.37 8.15 55 1.11 1.14 1.19 6.69 48 5.98 43 5.17 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Revenue / Patient (₹) EBITDA / Patient (₹) ROE % ROCE % +32% +68% 2264 2118 7
Slide 48: Statement of Profit & Loss (Consolidated)
Statement of Profit & Loss (Consolidated) Particulars (₹ million) FY26 FY25 FY24 FY23 FY26 vs FY25 FY23-26 CAGR (%) Revenue from Operations 3,104.14 2520.93 2187.09 1901.34 Other Income 31.6 38.46 35.51 35.53 Total Revenue 3135.78 2559.39 2222.59 1936.87 22.5% 17.4% Cost of Material Consumed 364.75
Slide 49: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) Particulars (₹ million) FY26 FY25 FY24 FY23 Particulars (₹ million) FY26 FY25 FY24 FY23 Assets Equity Non-current assets Equity share capital 104.16 104.16 85.29 85.29 Other equity 2,344.32 2,008.24 1,725.1 1,490.26 Property, plant and equipment 1,935.78 1,471.37 1,350.5
Slide 50: Statement of Cash Flows (Consolidated)
Statement of Cash Flows (Consolidated) Particulars (₹ million) FY26 FY25 FY24 FY23 Profit before Tax 445.57 414.05 314.53 67.48 Adjustment for Non-Operating Items 526.22 428.61 413.29 397.12 Operating Profit before Working Capital Changes 971.79 842.67 727.82 464.6 Changes in Working Capital -19.92
Slide 51: Thank You
Company : Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 investors@surakshanet.com Email: investors@surakshanet.com Investor Relations Advisors : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services Mr. Sumeet Khaitan sumeet.khaitan